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Abstract
The lack of medication for allergy symptoms at the end of the last millennium has been 
the promoter of the idea of treating allergies as if you were treating an infectious disease, 
by vaccination prophylaxis. Two forms of AIT 1) subcutaneous immunotherapy (SCIT) 
and 2) sublingual immunotherapy (SLIT) are used in the world. Considerable interest has 
emerged in SLIT both scientifically and especially financially. SLIT is not a new treatment 
modality. First description dates back to 1900 when H. Curtis. It was relatively widely 
used until the late 1970’s mainly in US by homeopathic therapists.
A number of case series describing experience with the oral route were published during 
the 1920s and 1930s, but it seems to have been perceived not as efficacious nor as well 
tolerated as subcutaneous immunotherapy. The companies producing allergen immuno-
therapy have an alliance with important opinion leaders on both shores of the Atlantic.
If SLIT did not work for 40 years, why should it work for respiratory allergic diseases 
today? This question is the mother of all questions in the field of respiratory allergic 
diseases. The purpose of this chapter is to provide past and current information about 
immunotherapy, and discuss controversies over efficacy and safety, and dosing consid-
erations for SLIT to grass.
Keywords: subcutaneous immunotherapy (SCIT), Sublingual immunotherapy (SLIT), 
Allergic rhinitis, Grass pollen, Evidence-Based Medicine
1. Background
For everything there is a season. This sentence from the Bible indicates and explains the his-
tory of sublingual immunotherapy (SLIT) in a nutshell. We must remember that allergy 
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treatment is a hybrid specialty. Respiratory diseases that come to the allergist are not 
uniquely his, but are shared with other specialties. Of the two major manifestations of 
respiratory allergic diseases, asthma and hay fever, the internist and pneumologist have 
plenty of opportunities to observe asthma and nose-and-throat specialists have great famil-
iarity with hay fever.
The drugs given for relief of allergic symptoms are familiar to physicians in general. After the 
characterization of immunoglobulin E (IgE) in 1967, a variety of in vitro tests to detect it and 
quantitative serum specific IgE have been developed. In vitro testing has since become more 
common [1].
Consequently, of two areas belong exclusively to the allergist, in vivo testing and allergen 
immunotherapy, only the latter has remained, used exclusively by allergists. Although AIT 
has been used to treat allergic rhinitis for over 100 years, its role remains controversial. AIT is 
accepted in full by most allergists, but only with many reservations by other medical special-
ists of diseases of the respiratory tract. Currently, two forms of AIT (1) subcutaneous immuno-
therapy (SCIT) and (2) sublingual immunotherapy (SLIT) are used in the world. Considerable 
interest has emerged in SLIT both scientifically and especially financially.
Compared with SCIT, SLIT is easy to administer, does not involve administration of injections 
and may be administered at home, avoiding the inconvenience of office visits and finally it can be 
prescribed by general practitioners, otolaryngologists and dermatologists as well as allergists [2].
In the mid-1950s, antedating by several years the more recent publications dealing with SLIT 
by Europeans, [3] a group of Midwestern physicians, headed by Dr. Herbert J. Rinkel, prac-
ticed a form of unconventional allergy that included a technique of administering prepara-
tions of allergenic extract beneath the tongue [4]. Rinkel changed the oral route suggested by 
Curtis 11 years before Noon’s publication on subcutaneous immunotherapy [5].
A number of case series describing experience with the oral route were published during the 
1920s and 1930s, but it seems to have been perceived not as efficacious nor as well tolerated as 
subcutaneous immunotherapy. Subsequently, the method fell out of favor [6, 7].
The genesis of this procedure, like all homeopathic therapies, was engendered by a strong 
belief, considerable imagination and although successful according to anecdotal reports from 
its practitioners, the technique lacked the rigor of scientific proof [8, 9].
The value of SCIT to the allergist was unquestioned until 1998. The allergist often asks 
skeptics of SCIT: how could SCIT has survived to this day, unless it was of genuine value? 
Unfortunately, the value of AIT is not to be determined by the fact that this procedure has 
survived a century. Bloodletting in medicine lasted for a much longer time as a therapy for 
pneumonia [10], but today it is not considered a rational therapy.
However, evidence-based medicine must be taken into account in the field of medicine, 
which is based on rigorous research and the scientific method. The companies producing 
allergen immunotherapy have an alliance with important opinion leaders on both shores of 
the Atlantic [11].
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A search of published literature under the topic “sublingual immunotherapy and RCT” 
revealed 24 citations in English before 2000 and 102 citations after 2000 (inception to July 
30, 2016), demonstrating the growing interest of companies and opinion leaders in SLIT for 
allergic rhinitis.
However, the medication for allergic rhinitis currently in use is highly effective and nasal 
steroids are of particular value [12].
In some ways it would be the same as supporting the use of cromolyn for the therapy of aller-
gic rhinitis rather than nasal steroids. A significant obstacle in evaluating the clinical value 
of SLIT is choosing the best criteria to prove clinical efficacy. Our position is that the best 
indication of efficacy is improvement in symptoms and decrease in medication that contrib-
utes significantly to the patient’s quality of life. The optimal study design for investigating 
clinical efficacy to evaluate SLIT includes pretreatment monitoring of symptom score for a 
season. This gives the advantage of elucidating the clinical relevance of allergen exposure in 
eliciting symptoms, representing the only possible way of ensuring an equal balance of dis-
ease severity in active and control groups. The magnitude of the clinical improvement is also 
important. It is of course critical to document a statistically significant difference between the 
active group and the control group, but p-values do not per se guarantee the effectiveness of a 
specific treatment. In 1991, Varney documented that immunotherapy has a clinical capacity 
to reduce, in actively treated patients, symptoms and drug intake by about 20% compared to 
the placebo-treated group [13].
If sublingual immunotherapy (SLIT) did not work for 40 years, why should it work for respi-
ratory allergic diseases today? This question is the mother of all questions in the field of respi-
ratory allergic diseases. The purpose of this chapter is to provide past and current information 
about immunotherapy and discuss controversies over efficacy and safety and dosing consid-
erations for SLIT to grass. Allergy to grass is the most important form of seasonal pollinosis.
Several persistent misconceptions or “false beliefs” have been built up around AIT and 
its use in allergic rhinitis (AR), in particular regarding sublingual immunotherapy (SLIT). 
These misconceptions largely arose because of improper use of evidence-based medicine that 
was widespread in this field until the 1990s.
2. Evidence-based medicine (EBM)
Initially EBM was identified with the frequency with which you reach health interventions 
proven effective (more helpful than harmful) and which prevents interventions more harm-
ful than useful. Three Doctors, an Englishman, Archie Cochrane, an American, Alan Feinstein 
and a Canadian David Sackett, can be considered the founders of this movement [14].
They identified the combination of carrier EBM in the interaction between research evi-
dence with patient preferences. This paradigm was, however, revised by Sackett in 1996 in 
an article published in the BMJ that clarified that EBM cannot be considered without also 
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considering that clinical expertise. Only research or expertise alone could not be consid-
ered EBM [15].
In 2002, Haynes et al. quoted a famous phrase from Osler, “The value of experience is not 
much to see but see wisely” and then EBM defers to center the patient that must be stud-
ied with the findings that emerge from research and patient preferences that all should be 
handled with the clinical expertise of the physician [16, 17].
A few years later Shekelle et al. classified the literature data on primary sources that include 
expert opinion, observational studies, case studies-final control, cohort studies, clinical tri-
als (RCT) and on secondary sources that include systematic reviews with or without meta-
analysis of RCT [18].
The importance of the evidence is maximum for systematic reviews with meta-analysis and 
the risk is minimal for bias in systematic reviews with meta-analyses. Secondary sources 
are always the representation of primary studies but should be guaranteed from the criti-
cal analysis of who writes them. They use an explicit method and systematic examination 
of primary studies. Finally, the tertiary sources are represented by evidence-based clinical 
guidelines [19].
The limits of primary studies are often related to sponsorships and thus influenced by the 
results, as reported by Ioannidis in this article a few years ago published in PLoS Medicine 
[20]. EBM is in crisis for the misuse and overproduction of primary studies, often useless 
because they duplicate other studies and in publication of therapeutic advantages with mar-
ginal shift of attention from individual research to therapy [21].
For these reasons, the EBM approach must be reevaluated critically, trying to customize the 
decisions not only by referring to the available evidence or patient preferences or adherence 
to therapy but also considering the cultural and financial aspects of the patient who must 
decide, investment in training doctors both in pre and postgraduate education and indicating 
the use of secondary studies rather than primary ones [22–25].
3. From subcutaneous immunotherapy to sublingual immunotherapy:  
the return to the past
In a document published in 1993 in allergy about immunotherapy, the authors wrote in the 
preface: why does a diagnostic etiology in a patient with allergic respiratory disease indicate 
the specific therapy as the only logical solution of this specific diagnosis [26].
Immunotherapy is the scientific path that Leonard Noon published in the Lancet in 1911 
[27]. The route was started by Bostock who described hay fever, i.e., allergic rhinitis and that 
proved to be the one that Backley demonstrated to be caused by grass season [28]. The stud-
ies of immunotherapy by Noon (who died prematurely from a form of tuberculosis), were 
continued by the pioneer John Freeman [29, 30]. It is necessary to remind readers that the use 
of antihistamines was reported in 1952 [31].
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However, the lack of medication for allergy symptoms has been the promoter of the idea of 
treating allergies as if you were treating an infectious disease, by vaccination prophylaxis [32].
In other words, the comparison between immunotherapy and placebo was based for many 
years on two symptomatic criteria: the number of days during the season in which eye symp-
toms were noted; the number of days in which nasal symptoms were noted [27, 29, 30].
Immunotherapy has spread rapidly around the world and the first study compared to pla-
cebo was done by Frankland and published in Lancet in 1954 [33]. Another study was per-
formed on ragweed in the United States and published in the New England J Medicine [34].
From a purely subjective assessment of both the patient and the allergist, the outcome of the 
studies is beginning to consider the evaluation criteria more objectively. At the end of the 
1960s, the number of antihistamine pills taken for the relief of symptoms was evaluated [35].
However, a sort of skepticism around this therapy remained until Ishizaka and Johansson 
discovered IgE and showed that they were the cause of allergic reactions [36, 37].
The fact that the antibodies played a role in patients treated with immunotherapy had already 
been suggested by Sherman et al. [38].
Finally, we must remember that chemical pharmacology was born in the nineteenth century. 
The first antihistamine was synthesized by Bovet and Staub in 1937, the molecule was the 2-iso-
propyl 5 methyl phenoxyethyldiethylamine, demonstrating mild antihistamine action and con-
siderable toxicity. In 1949, Bovet synthesized pyrilamine maleate, a diethylamine essentially free 
of toxic effects. But only in 1972, did Black et al. succeed in synthesizing antihistamines selective 
for the different receptors [39, 40]. Later, in 1974, beclomethasone dipropionate, became, the 
most important goal for the treatment of allergic rhinitis after that of antihistamines [41].
Allergy has been involved in a process of globalization. Before the 1980s there was no allergen 
standardization; this resulted in marked variations in allergenic strength among allergen vac-
cine batches produced in different phases. Immunotherapy was considered “Galenic” drugs, 
because they were prepared upon request of the allergist for a specific patient. The article of 
the Committee on Safety of Medicine challenges the use of ITS in the UK antihistamines and 
nasal steroids are marketed because they have been validated through controlled clinical tri-
als as effective and safe [42].
However, in a study published by Reid et al. the problem of fatal reactions as a result of ITS 
is now widely known [43]. Alarm about the safety of ITS, the use in clinical practice of anti-
histamines and nasal corticosteroids with fewer side effects, the lack of full understanding of 
the mechanisms of action of ITS bring specific immunotherapy into a crisis. International sci-
entific allergy companies, such as EAACI, produce important opinion-based scientific articles 
that, however, enhance the use of immunotherapy [44].
European allergists request single specific allergens for immunotherapy, rather than the 
allergen mixtures that had previously been requested and the companies, operating in 
the manufacturing sector of the allergen, participate more actively in the scientific debate. 
The companies begin to understand that the field of respiratory allergy, particularly that of 
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allergic rhinitis, is very rewarding financially. They also understand, however, that it is a field 
of medicine that is very closed and allergists are very jealous of AIT. They do not believe that 
it can be shared with other doctors [45–48].
In 1998, Malling published: immunotherapy as an effective tool in allergy treatment [49] in 
the allergy: a symposium review. The authors of this review stated on the bases of a number 
of DBPC studies, they could affirm that the clinical efficacy of immunotherapy in rhinitis and 
asthma, when potent and standardized extracts were applied in carefully selected patients, 
was well documented. Immunotherapy has the potential to reduce symptoms and the need for 
drugs significantly and furthermore possibly prevent progression into more severe disease.
SCIT has been evaluated on an arbitrary grading of the magnitude of clinical efficacy (Table 1).
Malling et al. wrote that: “this grading is arbitrary and controversial, but in daily clini-
cal practice it is more operational than statistical P values. Compared with the efficacy of 
drug treatment of allergic diseases, the grading seems sensible. A symptom/medication 
score amelioration of <30% does not seem to justify the immunotherapy involving a poten-
tial risk of side-effects and will probably not be considered worthwhile by patients” [49]. 
Fifteen RCTs investigated the efficacy of SCIT in grass-pollen allergy [13, 50–63], of which 
14 proved clinical efficacy. Only the RCT of Doltz et al. demonstrated a clinical effect of 10% 
improvement [62].
However, we must make two important observations: (1) SCIT is clinically effective, i.e., 
symptom/medication scores diminished by >30% in the actively treated in 72.3% of the 
studies and precisely in 93.3% of RCTs that investigated the efficacy of SCIT in grass-pollen 
allergy, in 69.2% of SCIT in ragweed, in 66.6% of SCIT in various allergens (Mountain cedar, 
Parietaria, Cupressus and Cocos) and in 60% of SCIT in DHM; (2) to satisfy an accurate indica-
tion for immunotherapy, this should be done by an allergist [49].
In other words, Malling et al. reiterate that only an allergist can decide if, when and how to do 
AIT. Certainly, this statement has not induced large investments from companies. However, 
the risk that AIT would remain a niche therapy managed only by allergists, is realistic.
In the same year, Malling et al. published a position paper of the European Academy of 
Allergy and Clinical Immunology entitled Local immunotherapy in allergy [3].
In this position paper, the authors examined the noninjective administration of specific immu-
notherapy in allergic disorders such as rhinitis and asthma, recommending to replace the 
1 No efficacy (symptom/medication scores improved by <30%)
2 Low efficacy (improvement 30–44%)
3 Moderate efficacy (improvement 45–59%)
4 High efficacy (improvement of >60%)
Table 1. Arbitrary grading of the magnitude of clinical efficacy by Malling [49].
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term “alternative immunotherapy” with “local immunotherapy” since the former may gener-
ate misleading associations and confusion with other, scientifically undocumented therapies 
used in allergic diseases, e.g., acupuncture, hypnosis, homeopathy and other methods [64]. 
Local immunotherapy included local nasal (LNIT), local bronchial (LBIT), oral (OIT) and sub-
lingual (SLIT) administration of allergen extracts.
Of these routes, both OIT and SLIT, like all homeopathic therapies, were engendered by a 
strong belief, considerable imagination and although successful, according to anecdotal 
reports from its practitioners, the technique lacked the rigor of scientific proof [8, 9].
The companies understand that SCIT would hardly be accepted by patients because the loss 
of time it takes is very significant—the time to go to the Allergist’s office, plus the time of the 
turn to take the shot, then wait at least 30 minutes after the shot. Overall, the time required for 
a shot was about 2 hours. However, it was necessary to give credibility to alternative routes 
of administration of specific therapy, using the methodology of evidence-based medicine. 
For this reason, Malling et al. presented the inclusion criteria of the studies in the chapter, 
reported in Table 2. We will report, as for SCIT (see above), only the studies for allergy to 
grass pollen, performed with four choices of local immunotherapy.
3.1. Nasal immunotherapy
The authors included only five RCTs with grass allergens and all studies showing clinical 
efficacy [65–69]. However, Malling et al. concluded that LNIT demonstrate “The side-effects 
do not appear to present a significant problem” [3].
3.2. Bronchial immunotherapy
RCTs for allergy to grass pollen with local bronchial immunotherapy (LBIT) have not been 
published. However, the comments about LBIT were the following words: “LBIT is not suf-
ficiently documented and there is concern about potentially serious immediate and delayed 
side-effects” [3].
While Crimi’s RCT about LBIT concluded that: “We conclude that LIT may be an effective and 
safe alternative to traditional immunotherapy” [70].
1 Placebo-controlled, double-blind (PCDB) studies
2 Allergen extracts and doses defined
3 Treatment protocol and statistical analysis appropriate including an adequate sample size (over seven 
patients per group)
4 Studies published in peer-reviewed journals in English
5 Symptom/medication scores provided.
Table 2. Criteria used in position paper published in Allergy in 1998 [3].
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3.3. Oral immunotherapy
The authors examined three RCTs with grass [71–73]. None of these RCTs demonstrates clini-
cal efficacy. The authors concluded that: “Only two studies indicate clinically relevant efficacy 
with either birch pollen administered in enteric-coated capsules or after treatment with aque-
ous mite extract for at least 1 year” [3].
3.4. Sublingual immunotherapy
The author considered only two RCTs with grass [74, 75]. Considering these two studies, 
the major innovation in the field of allergy is the presence of employees of the company that 
manufactures and sells the SLIT in the authors of the publication. Another important consid-
eration is that Bjorksten, coauthor of this chapter, wrote an Editorial about the RCT of Sabbah 
entitled: “Local immunotherapy is not documented for clinical use” [76].
The comment of the authors about sublingual immunotherapy was: “Sublingual immuno-
therapy has been shown to reduce rhinitis symptoms and/or medication needs in six RCTs. 
The documentation of efficacy is based on a limited number of studies including around 
120 patients” [3].
However, Malling et al. had excluded two RCTs with grass from their review, because one 
did not supply data on allergen doses [77] and the other did not include a placebo group [78].
After Malling’s position paper, the largest systematic reviews of sublingual immunotherapy, 
which reported on two primary outcomes, i.e., symptom score (SS) and medication score 
(MS), were performed in 2003 [79] and updated in 2010 [80] and published in the Cochrane 
collaboration database.
These two systematic reviews of sublingual immunotherapy suggested that the SLIT benefit 
in symptom improvement and drug use reduction is higher than placebo. But, the conclu-
sions of the above mentioned meta-analyses were based on studies conducted in patients 
with allergies to both perennial and seasonal allergens, while the efficacy of SLIT for grass 
allergens was assessed by a subgroup analysis [79, 80]. However, other RCTs have been pub-
lished on SLIT with grass allergens for AR [81–86]. Two RCTs presented results that remain 
inconsistent and the overall assessment of the treatment efficacy is still difficult to evaluate 
[85, 86]. Fourteen other RCTs on grass were published between 2004 and 2009 [87–100].
Our in-depth meta-analysis found that in seasonal allergic rhinoconjunctivitis, SLIT with 
grass allergens provided a statistically significant improvement of symptoms and a signifi-
cant reduction of anti-allergic medication compared with placebo. The data from 19 RCTs rep-
resenting a pooled total of 1518 patients receiving SLIT and 1453 receiving placebo, indicate 
the available evidence is sufficient to conclude: (1) SLIT with grass allergens improves rhino-
sinusitis symptoms and reduces the use of anti-allergic medications compared with placebo 
but the overall effect is clinically modest, (2) prolonged pre-season treatment significantly 
increases the response rate, and (3) a course of treatment no longer than 12 months with a 
monthly allergen dose of 450mg seems to be the best treatment choice. However, further 
studies are needed to clearly determine the role of SLIT with grass allergens in children [101].
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Several reviews have reported an equivalent clinical efficacy between SCIT and SLIT for sea-
sonal allergic rhinitis to grass pollens [102, 103]. SLIT has also been shown to be relatively 
safe and fairly well tolerated. These features account for the increasing use of SLIT in Europe. 
Improved safety and easy administration compared with SCIT are important advantages 
[104]. However, the relative efficacy of SCIT and SLIT has not yet been clearly shown. The only 
published study comparing the two treatments has been performed without placebo  [85].
Therefore, to clarify this issue, we performed and published a meta-analysis to compare SCIT 
and SLIT with a fairly large number of double-blind, placebo-controlled trials on SCIT and 
SLIT (updating the previous published meta-analysis) [101] in patients with seasonal allergic 
rhinitis to grass pollens [105]. This meta-analysis of data from 36 RCTs, 10 with SLIT drops [75, 
81, 83, 87, 88, 92, 94–96, 98], 12 with SLIT tablets [82, 84, 89, 90, 91, 93, 97, 99, 100, 106–108] and 
14 with SCIT [13, 52, 54, 55, 61–63, 109–115].
These studies included a total of 3014 patients treated with immunotherapy and 2768 con-
trols who received placebo. They provide indirect evidence that in patients with seasonal 
allergic rhinoconjunctivitis to grass SCIT is more effective than SLIT in the control of symp-
toms and in the reduction of anti-allergic medication use. There is significant heterogeneity 
in the results of individual RCTs, in particular for SCIT studies, which raises some concern. 
However, any degree of heterogeneity is acceptable if both the predefined eligibility criteria 
for the meta-analysis are sound and the data are correct [116].
Some of the SCIT trials included in our analysis were performed more than two decades ago 
on small sample sizes, but the quality of the studies has been considered sufficient to justify 
their inclusion not only in our meta-analysis but also in some Cochrane meta-analyses [79, 80, 
117]. Our study suggests that the choice of SLIT is mainly based on safety reasons. In fact, the 
number of reactions requiring epinephrine was higher in SCIT RCTs (12 in 960 patients), than 
in SLIT RCTs (1 episode in 4046 patients). However, the number of mild to severe adverse 
events was higher in SLIT than in SCIT (Table 3).
Moreover, our data provide indirect evidence that SCIT with grass allergens is more effec-
tive than SLIT to improve symptoms and reduce antiallergic medication for seasonal allergic 
rhinoconjunctivitis. However, trials directly comparing the two different routes of immu-
notherapy are needed to confirm these data [105]. An ideal comparative study would be a 
SCIT SLIT
Treated Placebo Treated Placebo
Total EAs, no. 960 456 4046 1856
Total AEs/patients 0.86 0.50 2.13 0.99
Withdrawals for AE, no. 18 5 78 25
Withdrawals for AEs/patients % 0.0019 0.005 0.04 0.0013
Anaphylactic reactions, no. 12 2 1 0
Table 3. Total adverse events (AE) related to SCIT and SLIT [105].
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 randomized, placebo-controlled, double-blind, double-dummy study that enrolls a large 
number of patients from a single center or a single country or a few countries with similar 
pollen exposure and patients of similar ethnicity. The treatment should be started at least 16 
weeks before the expected beginning of the pollen season and last 1 or 2 years. A vaccine with 
a dose of the main extract ≥275 mg for SLIT should be used. The ideal dose for SCIT vaccines 
has yet to be determined. Nonetheless, no one should be surprised by the criticism of our 
meta-analyses because the critics are authors who supported the use of SLIT [118, 119].
The convenience and safety of sublingual immunotherapy (SLIT) are likely factors for its 
widespread use in Europe, where it is now the preferred route of administration of ASI and 
were licensed as drugs in September 2009 (Grazax®, Alk-Abellò; Oralair®, Stallergenes) [120].
The US Food and Drug Administration (FDA) announced approval of the five-grass pollen 
sublingual tablet (Oralair®) in April 2014, followed by the Timothy grass pollen sublingual tab-
let (Grazax®/ALK-Abellò, marketed by Merck in the US under the name of Grastek®) [121–123]. 
SLIT with liquid allergen extracts had been used off-label in the US before FDA approval [2].
Our previous meta-analysis showed that SLIT was effective for seasonal allergic rhinocon-
junctivitis to grass, but its cl vinical benefit compared to placebo was modest [101, 105]. That 
data also showed that SLIT tablets are more effective than drops, probably because of a higher 
allergen content. All of the RCTs of SLIT published at that time had been performed in Europe 
[82, 84, 89–92, 97, 99, 100, 106, 124]. But since then five additional RCTs have been published, 
all conducted in North America. [107, 108, 125–127].
In our meta-analysis on SLIT tablets [128], data on symptom score were available in 13 RCTs [82, 
84, 89, 90, 91, 92, 97, 99, 107, 108, 125–127], and data on medication score in twelve studies [82, 
89, 90, 91, 92, 97, 99, 107, 108, 125–127]. We excluded the Caffarelli study, because he used an 
allergoid, Lais [106] and Horak study because it was performed in an allergen challenge cham-
ber [100] and the Halken study [124], which is a secondary analysis on a previously published 
dataset [102]. The 13 RCTs included a total of 4659 patients. Seven studies were conducted in 
Europe [82, 84, 89, 90, 92, 97, 99] and five in North America [107, 108, 125–127] and one in both 
Europe and Canada [91].
The SS and MS were assessed as outcome measures of the treatment effect. Outcome data 
were continuous, but different scoring systems and scales for symptoms and medication 
were used by the authors. To compare the results, analyses were performed by the method 
of standardized mean difference (SMD), expressing the differences in means between SLIT 
and placebo in terms of units of the pooled SD. The overall SMD among patients treated with 
SLIT and placebo was estimated using models based on both fixed effects and random effects 
assumptions [129]. The magnitude of the overall effect was classified according to Cohen’s 
guidelines: effect size of 0.2, 0.5, and 0.8 correspond to small, medium and large effects [130]. 
Since 11 out of 13 RCTs used the same SS ranging from 0 to 18 points (the higher the score 
the worse the disease severity) as outcome measure, we compared the results of these studies 
using the original SS, reporting the results as mean difference (MD) of SS-points. Excluding 
the studies by Pradalier [82] and Smith [84], we could compare the studies using the original 
SS, which is easier to interpret. Using this method the mean difference between SLIT and 
placebo was −0.83 SS points (95%CI −1.03, −0.63, p = 0.0001) without significant heterogene-
ity (I2= 16%). The SMD excluding these two studies did not change compared to the main 
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analysis performed with 13 studies (SMD −0.28, 95%CI, −0.39, −0.18; p < 0.0001), indicating 
that SMD of −0.28 corresponds to a MD of −0.83 SS points.
Data on medication score were obtained for 12 RCTs (4558 patients) [82, 89, 90, 91, 92, 97, 
99, 107, 108, 125–127]. A statistically significant difference between SLIT and placebo was 
observed only in seven RCTs [89–92, 97, 125, 127]. The pooled estimate of treatment on medi-
cation score was statistically significant (SMD −0.24; 95%CI, −0.31, −0.17; p < 0.0001). An analy-
sis using the original medication score was not performed due to the highly different scoring 
systems used. A total of 1817/2597 (70.0%) of patients receiving SLIT vs. 1137/2555 (44.5%) of 
subjects receiving placebo complained of adverse events. Probable treatment-related adverse 
events were reported in 9 out of 13 studies and there were three times as many adverse 
events in patients receiving SLIT (1384/2259, 61.2%) than in those receiving placebo (477/2279, 
20.9%). Most AEs were moderately severe for both groups. The withdrawal rate for an AE was 
higher in the SLIT group (159 patients, 6.0%) than in the placebo group (56 patients, 2.2%). No 
episode of anaphylaxis was reported in the RCTs; but nine adverse events requiring epineph-
rine were reported in the SLIT group, of which seven were treatment related. Three serious 
adverse events requiring epinephrine were also reported in the placebo group, but none of 
them were treatment related (Table 4). The forest plot and the funnel plot of the data reported 
above can only be seen in the original publication due to copyright [128].
SLIT Placebo OR P
Total AE, # patients (%) 1817/2597 (70) 1137/2555 (45) 2.91 <0.0001
TRAE, # patients (%)† 1384/2259 (61) 477/2279 (21) 5.98 <0.0001
Withdrawals for AE, # patients (%) 159/2658 (6) 58/2587 (2) 2.77 <0.0001
Anaphylactic reactions 0 0 – n.s.
AE requiring adrenaline 9 3 – n.s.
TRAE requiring adrenaline 7 0 – n.s.
Note: AE, adverse events; TRAE, treatment-related adverse events.
Table 4a. Adverse events during treatment [128].
TRAD SLIT n (%) Placebo p #Studies
Oral pruritus 689/2228 (30.9) 84/2126 (3.9) <0.00001 11/13
Throat irritation 418/2045 (20.4) 71/2006 (3.5) <0.00001 9/13
Mouth edema 226/2105 (10.7) 17/2033 (0.8) <0.00001 9/13
Ear pruritus 181/1524 (11.9) 32/1444 (2.2) <0.00001 6/13
Eye pruritus 81/852 (9.5) 20/768 (2.6) <0.00001 4/13
Oropharyngeal pain 122/1306 (9.3) 33/1309 (2.5) <0.00001 4/13
Note: Other side effects, such as headache, cough, tongue pruritus, sneezing, rhinorrhea, nasal discomfort and 
nasopharyngitis, have not been reported in the table since they were reported in less than four studies.
Table 4b. Most common treatment-related adverse events (TRAE), occurring in at least 5% of patients in the treatment group.
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4. The methodological problem used to evaluate the tablets grass
In the last part of this chapter, we will focus on the most critical methodological defect of the 
SLIT RCTs, which is the metric that has been used in RCTs to assess the clinical benefit. This 
metric is mathematically incorrect because, as clearly will explained in the study, it calculates 
the percentage difference between SLIT and placebo, not taking into account the symptom 
score (SS) scale range and leading to a huge magnification of the difference between groups.
By using this metric, a 1-point difference will be the same percentage difference in an 18-point 
scale (the te common SS scale used), a 100-point scale, or any other scale, and this is math-
ematically unacceptable (a detailed explanation has been reported in Figure 1).
The correct metric, which takes into account the scale range, was indicated by the World 
Allergy Organization (WAO) [104].
Recommendations for standardization of clinical trials with allergen and is based on the 
comparison between the pretreatment and post treatment SSs of the active and placebo 
groups. Using this metric, we showed a small difference between SLIT and placebo, which 
is less than the US Food and Drug Administration (FDA) (15%) and WAO (20%) thresholds 
of efficacy. The baseline in the case of SLIT RCTs is the retrospective (prior year) total 
symptom score (RTSS), which is used by the investigators of the original RCTs as inclusion 
criteria. In other words, the RTSS is assumed by the investigators as the SS that the patients 
would have in the absence of any treatment (corresponding to the inclusion criteria). We 
acknowledge that the RTSS might be imprecise, but it should be similar to the SS of the 
treatment season, especially if the pollen count of the two consecutive seasons is similar, 
and we have shown for the Cox study, performed with 300IR 5-grass pollen sublingual 
tablet (Oralair®) in only US sublingual study, that this possible imprecision does not affect 
the results [102].
Figure 1. 18-point scale.
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In our meta-analysis [128], we reported the difference between SLIT and placebo not only 
in terms of the standardized mean difference (SMD) but also in terms of the mean differ-
ence (MD), which is the difference in SS points between SLIT and placebo. We showed that 
this difference is −0.83 SS points (95% CI, −1.03 to −0.63). In a recent work, Devillier and the 
Stallergenes©, an industry that market the SLIT, estimated the minimally important differ-
ence, which is defined as the smallest improvement considered worthwhile by a patient, as 
1.1 to 1.3 SS points in patients with grass pollen-related rhinoconjunctivitis [131].
Therefore, according to the Devillier estimation, the difference that we found (−0.83 SS points) 
between SLIT and placebo is not perceived by the patients as clinically important, confirming 
the conclusions of our previous study. In Figure 2, we reported the 95% CI for the mean value 
(−1.03 to −0.63 for the random effect and even smaller for the fixed effect). This implies that we 
are 95% confident that this interval contains the true value of the parameter. Therefore −1.03 
could be a value for the population parameter: even if it was the true value (the most favor-
able extreme to SLIT), the probability of observing a value of less than −1.1 is only 0.25 (25% of 
patients could benefit significantly from SLIT). In contrast, if the true value was that reported 
in our study as a point estimate, less than 0.5% of patients can show an improvement of greater 
than −1.1. This is in accordance with the calculation using our metric reporting an SS reduction 
to less than the WAO (20%) and FDA (15%) thresholds of efficacy.
Regarding safety of the AIT, on the basis of what is reported in RCTs the majority of adverse 
events are mild to moderate and that “both SCIT and SLIT are very safe” [132] but as we 
showed in our previous meta-analysis [105] indirectly comparing SCIT and SLIT, the with-
drawal rate for adverse events was higher in the SLIT group (78 patients; 0.04% vs 0.013% 
in the placebo group) than in the SCIT group (18 patients; 0.019% vs 0.005% in the placebo 
group). This evidence should also be considered.
Figure 2. Hypothetical 100-point scale, with a hypothetical RTSS (baseline score) = 95, congruent with a 100-point 
scale.) RTSS, retrospective total symptom score (baseline). With the calculation shown in RCTs (horizontal arrow) only 
the mean SS during the treatment is considered, ignoring the scale range. In WAO indicated calculation, the same we 
propose (vertical arrow), the scale range is included. The inclusion of the scale in the calculation changes the percentage 
of the improvement, even if the difference between the two groups remains the same.
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5. Conclusions
Regarding the physician-patient dialog to respect patient preference according to evidence-
based medicine principles [15, 16], we believe that in the case of SLIT, the patient has to be 
informed correctly about the small benefit of the treatment.
In the interest of patients, caution must be exercised when such a small treatment benefit is 
reported, especially if one considers that sponsored studies (as in the case of all SLIT RCTs) 
always show greater benefit compared with independent studies using the same drugs or 
devices [133, 134].
This chapter shows that there is an increasing interest in risk-sharing schemes by both pay-
ers and manufacturers, as they serve as mechanisms for reduce uncertainty in collecting 
evidence once a new drug is already being used in a health care system. In principle, they 
could provide additional options to payers and manufacturers, to boost overall efficiency 
[135]. The ambitious goal is to help reduce the likelihood of payers adopting technologies 
that turn out not to be cost effective, while at the same time helping manufacturers earn 
profitable prices to invest in future innovative technologies. Italy is one of the countries that 
started early with these agreements: AIFA, the Italian drug agency, agreed on its first con-
tract in July 2006 [136].
The regulatory authorities such as the US Food and Drug Administration (FDA), the European 
Medicines Agency (EMA) and the Japanese Medical Device Agency are responsible for the 
approval of any drug. Academia (including universities, scientific institutions and societies) 
is another major stakeholder with an important role in influencing the behavior of prescrib-
ers. Patients and consumer associations have also an important role: patients are involved in 
RCTs, consumers associations are consulted in decision concerning research priorities.
Finally, pharmaceutical companies maintain a sort of monopoly in development of new drugs 
and promote the drug and the sales [137]. In the European Union (EU), as well as in US, 
medicines are authorized by the European Commission (EC) and Federal Trade Commission, 
respectively. After a positive evaluation by the European Medicine Agency (EMA), Food Drug 
Administration (FDA) uses the centralized procedure or the national agencies through decen-
tralized procedures. According to the EU legislation and provisions of the FDA, the evaluation 
of medicines seeking marketing authorization is only based on their quality, safety and effi-
cacy. No information is required on their comparative efficacy with respect to drugs already 
available. In our case, SLIT has been compared only with placebo in all RCTs, the indirect com-
parison between SCIT and SLIT has shown that the SCIT is superior to SLIT [105]. After our 
meta-analysis, other studies have been published that concluded that SLIT has at least non-
inferior efficacy and comparable safety compared to SCIT, but a lower annual cost [138, 139].
Our review provides moderate-grade evidence to support that SCIT is superior to SLIT for 
reduction of allergic rhinoconjunctivitis symptoms. Finally, we do not discuss the consider-
ations on the disease-modifying effects of AIT, because they have been evaluated in another 
study that is difficult to get published because of the obvious conflict of interest in peer review 
which is responsible for reviewing the manuscript [140].
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